Introduction {#S0001}
============

Nanotechnology-based materials, nanoparticles in particular, have gained significant attention in biomedical fields with their substantial advantages in both efficacy and safety over conventional pharmaceutical agents.[@CIT0001]--[@CIT0003] Through manipulating molecules and atoms at the nanoscale, one can fabricate functional nanoparticles that can be used in therapeutic and diagnostic modalities.[@CIT0004]--[@CIT0008] For instance, nanoparticles can be formulated with inorganic metallic substance such as gold (Au),[@CIT0009] silver (Ag),[@CIT0010] iron (Fe),[@CIT0011] copper (Cu),[@CIT0012] titanium (Ti)[@CIT0013] and zinc oxide (ZnO),[@CIT0014] employed commonly in the detection, diagnosis, and therapy of several diseases such as protozoal, bacterial and fungal infections.[@CIT0015]--[@CIT0022] Furthermore, The development of biomacromolecule-based drug delivery carriers, such as albumin, peptides and polysaccharides, for effective delivery of therapeutic compounds or imaging agents, is crucial in the battle against various diseases.[@CIT0023]--[@CIT0027] As their inherent biochemical and biophysical properties including renewability, nontoxicity, biocompatibility, biodegradability and potential biological ability, the exploration of biomacromolecule nanoparticle is now considered to be an essential respect in the drug and medicine field.[@CIT0028]--[@CIT0031]

Helix-forming β-glucans, such as curdlan (CUR), yeast β-glucan (YSG), lentinan (LTN), schizophyllan (SPG) and their derivatives have been extensively exploited in the recent two decades as chiral "hosts" to encapsulate/wrap a wide range of "guests" to form drug/DNA/RNA delivery systems, optical/electrical nanodevices, or organic template to organize gold/silver/carbon nanostructures.[@CIT0032]--[@CIT0035] The development of β-glucan drug carriers has garnered an increasing attention owing to its special chiral interaction with bioactive molecules.[@CIT0036]--[@CIT0038] The supramolecular interactions between β-glucans and pharmaceutical molecules can be based on chiral interactions, instead of using excessive electrostatic/hydrophobic interactions, which are frequently adopted by conventional polymer drug delivery systems that may cause denaturing of tissue proteins and bring damage to the cell membrane.[@CIT0039] In addition, β-glucan itself has a well-established immunopotentiation ability with low toxicity, demonstrated in clinical trials (YSG).[@CIT0040] Such adjuvant property may become a "plus" when β-glucan is developed as an anti-cancer drug delivery material. More importantly, the helical motif in β-glucan carriers can also function as a chiral "tag" to track the drug encapsulation or release with the aid of circular dichroism spectroscopy. Therefore, β-glucan is worthy of investigation as an anti-cancer drug carrier based on its unique chirality, immunological property, and self-assembling ability.

In previous studies, β-glucan materials were evaluated as carriers for anti-cancer drugs, especially for the model drug doxorubicin (DOX). However, these studies only regard β-glucan as a plain polysaccharide to carry DOX by non-specific absorption; the helical properties of β-glucan were largely neglected. For example, decellularized yeast cells consisting of β-glucan were directly used as DOX carriers,[@CIT0041] despite the size of the yeast shell being measured in micrometers, making it too large as an ideal DOX carrier. Zhou and his coworkers developed hydrophobically modified CUR nanoparticles to load DOX; however, the chirality and bioactivity of β-glucan may be lost due to the extensive chemical modification.[@CIT0042] Meng and his coworkers developed unique self-assembling dendritic nanostructures based on fungal β-glucan as DOX carrier.[@CIT0043] However, the relationship between chirality and DOX encapsulation is unclear. Thus, a simpler and more efficient self-assembly approach is needed to explore the chirality and helix-forming nature of β-glucan as an advanced DOX carrier.

The aggregation behavior of β-glucans in solution varies greatly depending on their chain structures, which are also associated with their biological origin. Bacterial β-glucans, such as CUR, have limited solubility in water and tend to form large aggregates driven by hydrophobic interaction.[@CIT0044] On the other hand, fungal β-glucans (LTN/SPG) are fairly soluble in water and tend to exist in the form of well-dispersed triple helices.[@CIT0045] In comparison, the solubility of YSG lies between CUR and LTN, and it tends to take the form of micro-nano particles due to the presence of long hydrophilic branches on the main chain.[@CIT0046] In our previous study, we successfully prepared a series of depolymerized or esterified YSG, but their chiral properties and drug carrying abilities have not been investigated.[@CIT0047] We also investigated the self-assembly of CUR in DMSO/water system that led to a formation of nanofibers.[@CIT0048] In this study, we continue to investigate the denaturing/renaturing of YSG in the presence of DOX in an attempt to construct novel chiral nanocarriers (NCs). The major hypothesis is that the unique chirality of β-glucan can be exploited by self-assembly to encapsulate and deliver DOX with an adjuvant immunopotentiation effect. Four different self-assembling YSG-derived nanostructures were evaluated and coded as YG, GG, SSG, and BG. YG, in particular, is obtained by DMSO-mediated renaturing of YSG. GG is obtained by pH-induced renaturing of YSG. SSG is developed from pH-induced renaturing of depolymerized YSG while BG is from DMSO-mediated renaturing of hydrophobically modified YSG (butyrylated YSG). The denaturing/renaturing of these β-glucan compounds was in the presence of DOX to trigger the formation of drug delivery systems. Moreover, their nanostructure, chiral fingerprints, and drug-loading properties were extensively characterized using UV-Vis, CD, FT-IR, TEM, DLS analysis. The immunological properties of the drug carriers were tested by expression of cytokines from a RAW264.7 cell model while in vitro their delivery properties were investigated using a human breast adenocarcinoma cancer cell model.

Materials and Methods {#S0002}
=====================

Reagents and Cells {#S0002-S2001}
------------------

YSG from Baker's yeast was purchased from Tiantian Bioengineering & Technology Co., Ltd (China). Doxorubicin (DOX) were purchased from Macklin (Shanghai, China). Depolymerized YSG and Butyrylated YSG were prepared according to our previous work.[@CIT0047] Dulbecco's modified eagle medium (DMEM, glutamine, high glucose), penicillin, streptomycin and fetal bovine serum (FBS) were purchased from HyClone (USA). 4′,6-diamidino-2-phenylindole (DAPI) was purchased from Sigma-Aldrich Co. (St. Louis., MO, USA). Dialysis tube (MW cutoff, 1.4 kDa) was purchased from Spectrum Labs (Seoul, Korea). Other reagents used in this work were purchased from Aldrich unless otherwise specified. The human breast cancer cell line (MCF-7) and the mice monocytes-macrophages cell (RAW264.7) both were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China).

Preparation of YG-DOX, GG-DOX, SSG-DOX, BG-DOX NCs {#S0002-S2002}
--------------------------------------------------

NCs-DOX was prepared in two different self-assembly methods: DMSO-mediated self-assembly and pH-induced self-assembly. For the YG-DOX and BG-DOX, the powder of YSG and BG were dissolved, respectively, in DMSO (10 mg/mL, 1 mL) for over 2 hours in the presence of DOX (1 mg/mL, 1 mL). Then 9 mL deionized water was added into the solution, followed by dialysis against plenty of water for two days to remove the free DOX. For GG-DOX and SSG-DOX, powder of YSG and SSG were suspended in deionized water (1 mg/mL, 9 mL) respectively. To the suspension, NaOH solution was added to adjust the pH to 13.0. Then, 1.0 mL of DOX water solution (DOX: 1.0 mg/mL) was added and the resulting mixture was stirred for 5 min. Next, HCl solution was added into the mixture solution to adjust the pH to 7.4. Similarly, after dialysis in plenty of water over two days to remove the free DOX.

Reverse-Transcription-PCR (RT-PCR) {#S0002-S2003}
----------------------------------

Total RNA was extracted from RAW264.7 cells using TRIzol reagent (Invitrogen Corp., USA), according to the manufacturer's instructions. cDNAs were synthesized from 1 μg of total RNA from each sample using a high-capacity cDNA reverse transcription kit (Applied Biosystems, USA) and were amplified with mouse-specific primers for IL-1β, IL-6, TNF-α, IFN-γ.

Drug Loading Capacity and Drug Release in vitro {#S0002-S2004}
-----------------------------------------------

The drug loading capacity (DLC) was defined as the weight percentage of DOX in the NCs and drug encapsulation efficiency (DEE) was defined as the weight percentage of loaded-DOX in the NCs and the given DOX. Firstly, DOX solutions of various concentrations were prepared, and the absorbance at 481 nm was measured to generate a calibration curve for the DLC and DEE calculations from various NCs.[@CIT0049] Secondly, in order to determine the DLC and DEE, 2.0 mg of lyophilized complex was dispersed in 1 mL of deionized water at room temperature, followed by dilution with 9 mL of DMSO to completely expose the encapsulated DOX. The obtained solution was examined by UV--vis spectroscopy at a wavelength of 481 nm. DEE (%) were calculated according to the following equations:

$$\documentclass[12pt]{minimal}
\usepackage{wasysym}
\usepackage[substack]{amsmath}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage[mathscr]{eucal}
\usepackage{mathrsfs}
\DeclareFontFamily{T1}{linotext}{}
\DeclareFontShape{T1}{linotext}{m}{n} {linotext }{}
\DeclareSymbolFont{linotext}{T1}{linotext}{m}{n}
\DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext}
\begin{document}
$$DEE (\rm %) ={\ }{{{\rm{the \ weight \ of \ drug \ loaded \ into \ nanogel }}} \over {{\rm{the \ weight \ of \ initial \ drug}}}} \times 100\%$$
\end{document}$$

The in vitro pH-triggered sustained release behaviors of NCs-DOX were performed at 37 °C in phosphate buffer saline (pH=7.4) and acetate buffer (pH=5.0). The NCs-DOX (0.5 mg) were dissolved in 1 mL phosphate buffered saline solution (PBS) and were placed in dialysis bags (MWCO 8000−12,000) and dialyzed against 19 mL of release medium under gentle shaking. At the expected time, 5 mL of the medium was removed and replenished with an equal volume of corresponding fresh release medium. The released DOX was determined by UV--vis measurement at a wavelength of 481 nm to calculate the accumulative DOX release profile, and the percentage release of the drug was plotted against time. All the drug loading and release experiments were performed in triplicate to determine means and SD.

Ultraviolet and Visible Spectrum (UV/Vis) {#S0002-S2005}
-----------------------------------------

Absorption spectra from the NCs-DOX solution were taken with a double-beam UV−vis spectrometer (Shimadzu UV-2101PC) in a 0.1 mm/0.2 mm demountable quartz cell (Hellmar GmbH, Germany) with the range of 450−550 nm.

Fourier Transform Infrared Spectroscopy (FT-IR) {#S0002-S2006}
-----------------------------------------------

FT-IR spectra of the NCs-DOX were recorded with a Nicolet 6700 spectrometer using KBr pellet method and all of the spectra were obtained at a resolution of 4 cm^−1^ and with a total of 32 scans with a wave number range between 500 and 4000 cm^−1^.

Circular Dichroism Spectra (CD) {#S0002-S2007}
-------------------------------

The CD spectra were recorded on a Chirascan CD spectrophotometer (Applied Photophysics, UK). CD spectra were determined over the range of 350−650 nm using a quartz cell with 0.1 mm path length. Scans were taken at a rate of 30 nm/min with a sampling interval of 1.0 nm and response time of 1 s at room temperature.

The Diameter and Size Distribution of Samples {#S0002-S2008}
---------------------------------------------

The diameter and size distribution of the obtained NCs were evaluated by dynamic light scattering (DLS, Malvern Nano-ZS, UK) at sample concentration 1.0 mg/mL.

Staining of the NCs and NCs-DOX Structures by PTA for TEM Analysis {#S0002-S2009}
------------------------------------------------------------------

Generally, 3 μL of various NCs (1 mg/mL) was loaded on a carbon-coated TEM grid for 30 s and then dried using filter paper. A droplet of 5 μL of 2% PTA aqueous solution was then loaded on the sample containing the TEM grid to achieve different staining effects and dried using filter paper.

Cell Culture {#S0002-S2010}
------------

RAW264.7 cell and MCF-7 cell were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, and 100 μg/mL streptomycin at 37 °C in a humidified atmosphere with 5% CO~2~.

Cellular Uptake {#S0002-S2011}
---------------

The cellular uptake of NCs-DOX and free DOX were measured by fluorescence image. Briefly, MCF-7 cells at logarithm phase were seeded in 24 well cell culture plates at a cell density of 2 × 10^4^ cells/well, respectively. After incubated for 24 h, NCs-DOX or free DOX dissolved in PBS at 5 mg/L was added to replace the media in each well. After further incubated for 4, and 12 h, the media were removed and these wells were rinsed with PBS (pH = 7.4). The cell nuclei were then stained with DAPI and were observed using a Nikon microscope (TE2000-U, Nikon, Japan). DOX was excited at 485 nm with the emission at 595 nm.[@CIT0050]

MTT Assays {#S0002-S2012}
----------

The therapeutic effect of NCs-DOX in vitro against the MCF-7 breast cells were incubated with free DOX and NCs-DOX for 24 hours and 48 hours, and the cell viability was measured by using a standard 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay.[@CIT0051] Briefly, MCF-7 cells were cultured in 96-well plates at a density of 4 × 10^3^ cells/well overnight to allow the cells to adhere onto the culture plate surface. Then, 100 μL of the culture media, in which the equivalent DOX concentrations were 0.125, 0.25, 0.5, 1.0, 5.0, and 10.0 ug/mL, respectively, were used to substitute the media in each well. Cells were subsequently incubated for 1 day and then evaluated by MTT assay. Untreated control cells were regarded as 100% viable and all values were expressed as a percentage of the control.

Results and Discussion {#S0003}
======================

Chemical and Chiral Fingerprints of YSG Derived NCs {#S0003-S2001}
---------------------------------------------------

[Figure 1A](#F0001){ref-type="fig"} shows the chemical structure and chain conformation of YSG. The chemical nature of the polysaccharides was verified by ^1^H NMR. As shown in [Figure 1B](#F0001){ref-type="fig"}, the chemical shifts of pristine YSG are consistent with the previous studies.[@CIT0047],[@CIT0052] The spectrum of depolymerized YSG is highly similar to the pristine one, indicating that the depolymerization process did not damage the glucosidic units. For the spectra of BG, the multiple sharp and strong peaks in the range of 0.8--2.3 ppm can be attributed to the protons of the newly grafted butyryl groups. The peaks in the range of 3.0--5.5 ppm, where the proton signals on the β-glucan backbones are dominant, weakened significantly after chemical modification, indicating a high degree of substitution (DS) of butyryl groups for BG. The DS of BG was further determined to be 2.6 by titration techniques.Figure 1Chemical structure and chain conformations of YSG (**A**). ^1^H NMR spectra of YG, SSG, and BG in d-DMSO (**B**). ICD spectra of YG, GG, SSG, and BG, complexed with Congo red (**C**).

The chiral fingerprints of the NCs were then characterized by induced circular dichroism (ICD). β-glucans can exist in architectures with different chiral characteristics in solution, but they cannot be directly examined by CD owing to the lack of chromogenic groups. Congo red (CR) can probe the chirality of the assemblies of β-glucans in solution.[@CIT0048],[@CIT0053] Although CR and β-glucans which have no CD signals, the chiral interaction of CR and helical motifs of β-glucan can lead to induced CD signals, and they are the chiral fingerprints of β-glucan nanostructures. As shown in [Figure 1C](#F0001){ref-type="fig"}, unesterified β-glucan NCs, including YG, GG, and SSG, show the strongest ICD bands at ∼520 nm (Band-C) near the max UV-Vis absorption band of CR, which indicates that helical motifs are dominant in these NCs. In addition, all of the three unesterified carriers show twin positive bands at \~380 nm (Band-A) and \~440 nm (Band-B), respectively. However, the relative intensity of Band-A to Band-B is different. The ratio Band-A/Band-B is the highest for SSG, which is followed by YG and GG. The subtle difference in ICD spectra indicates a different chiral nanostructure of the NCs, and may affect the drug loading ability and immunological activity. In contrast, BG-CR only shows particularly weak ICD signal from 350 nm to 650 nm, and the band at \~520 nm is nearly undetectable, indicating that chains of BG exist in random coil state.

The Immune-Potentiation Properties of β-Glucan NCs Evaluated by a RAW264.7 Cell Model {#S0003-S2002}
-------------------------------------------------------------------------------------

β-glucans have been used as anti-tumor adjuvants based on their immunostimulatory activities such as activation of macrophage/dendritic cells, but such property is strongly affected by the state of molecular aggregation and secondary structures. Therefore, whether YG, GG, SSG, BG NCs activate RAW264.7 cells were examined by analysis of the mRNA expression of IL-1β, IL-6, TNF-α, IFN-γ. The expression levels of IL-1β, IL-6, TNF-α, IFN-γ in NCs-treated (400ug/mL) RAW264.7 cells were examined by RT-PCR after 24 h of incubation. As shown in [Figure 2](#F0002){ref-type="fig"}, the chiral negative ones such as BG do not stimulate RAW264.7 cells whereas chiral positive ones, such as YG, GG and SSG can activate RAW264.7 cells. However, there is also subtle difference in the activation effects for the 4 types of cytokines.Figure 2Effects of YG, GG, SSG, BG NCs on the expression of IL-1β, IL-6, TNF-α, IFN-γ in RAW264.7 macrophages. Cells were cultured in the presence of NCs (400 μg/mL) for 24 h and the expression of IL-1β (**A**), IL-6 (**B**), TNF-α (**C**), IFN-γ (**D**) mRNAs was measured using RT-PCR. Relative increases in the levels of each band compared with the loading control β-actin. Values are expressed as the mean ± SEM of the three separate experiments. Each group compared with the NCs-untreated cells (0 μg/mL). \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.

This subtle difference can induce the increase of expression of IL-1β mRNA by 5.64-fold, the IL-6 mRNA by 193.89-fold and the TNF-α mRNA by 3.90-fold, respectively, for YG NCs. For GG NCs, it can induce the increase of expression of the IL-1β mRNA by 22.72-fold, the IL-6 mRNA by 27.62-fold, the TNF-α mRNA by 1.89-fold and the IFN-γ mRNA by 13.73-fold, respectively. For SSG NCs, it can induce the increase of expression of the IL-1β mRNA by 25.76-fold, the IL-6 mRNA by 30.73-fold, the TNF-α mRNA by 1.12-fold and the IFN-γ mRNA by 17.05-fold, respectively.

In summary, β-glucan can maintain the immunostimulatory activity when the chirality was maintained, and the subtle difference in chiral fingerprints may induce a different gene expression profile of cytokines. There is evidence that the state of aggregation of β-glucan may affect its induction of different set of cytokines; however, the exact structural-property relationship is still not very clear.[@CIT0054]

The DOX Encapsulation Ability of NCs {#S0003-S2003}
------------------------------------

[Figure 3A](#F0003){ref-type="fig"} shows the photographs of YG, GG, SSG, and BG NCs after DOX was encapsulated. The suspensions are highly homogenous and can remain stable for at least 2 months. As shown in [Table 1](#T0001){ref-type="table"}, the drug encapsulation efficiency of SSG-DOX, GG-DOX, YG-DOX and BG-DOX is 38.2%, 35.6%, 13.9% and 15.2%, respectively. This indicates that chiral fingerprints of NCs with such as a higher ICD Band-A/Band-B ratio are associated with a higher drug encapsulation efficiency.Table 1Drug Encapsulation Efficiency (Wt%) of NCs-DOXDOX0.511.52YG-DOX10.511.913.512.6GG-DOX26.835.635.336.5SSG-DOX29.038.239.336.4BG-DOX13.315.214.117.2[^2] Figure 3Photographs of the suspensions of DOX loaded NCs (**A**). Particle size and distributions of DOX loaded NCs measured by DLS (**B**). TEM images of the DOX loaded NCs (**C**).

DLS was used to measure the particle size and distribution of the drug-loaded NCs. As shown in [Figure 3B](#F0003){ref-type="fig"}, the size distribution of these DOX-loaded NCs ranges from 50 nm to 160 nm. GG-DOX has the smallest average diameter around 50 nm. BG-DOX showed the largest average diameter of \~150 nm. YG-DOX and SSG-DOX have a particle size around 100 nm.

TEM examination is used to analyze the morphology of DOX-loaded NCs. As shown in [Figure 3C](#F0003){ref-type="fig"}, YG-DOX has a gel like morphology and fibrous network can be observed inside. The fibrous network can be attributed to the bundles of β-glucan triple helices, which have been observed in previous studies.[@CIT0048] DOX may be entrapped in the water phase of the nano-sized gel. In contrast, GG-DOX exhibits a rectangular shape and a higher magnification image shows a lattice-like structure inside of the particles. We speculate that GG and DOX may have certain specific interaction, which leads to a formation of highly organized assemblies. As for SSG-DOX and BG-DOX, spherical nanoparticles can be observed, but SSG-DOX seems to be less dense than BG-DOX. Hydrophobic interaction may promote butyrylated β-glucan to aggregate more densely in water.

Chiral Interaction of β-Glucan NCs and DOX Studied by CD, UV-Vis, and FT-IR Spectroscopy {#S0003-S2004}
----------------------------------------------------------------------------------------

As DOX and β-glucan are both chiral molecules, possible chiral interactions were studied by CD spectra to reveal the drug loading mechanism of β-glucan NCs. DOX is a chiral molecule, which shows a split-type CD spectrum with a positive band at ∼450 nm and a negative band at \~530 nm near the max absorption of DOX in the visible light region. As shown in [Figure 4A](#F0004){ref-type="fig"}, when DOX was loaded into different NCs, the CD bands of DOX changed greatly, which reflects that DOX was loaded in different mechanisms. Strikingly, the CD bands of DOX were completely reversed when it was loaded into SSG, in which the highest drug loading efficiency was achieved. The drastic change in CD signals of DOX when encapsulated indicates that SSG and DOX may have highly specific chiral interactions. Also, when it was loaded in GG, the 530 nm band of DOX showed a significant upper-shift from negative zone to positive zone, indicating another type of chiral interaction of GG and DOX. However, the CD bands of DOX were nearly unchanged when loaded in YG, which shows a gel-like structure, indicating that the interaction is likely to be a non-specific physical absorption. The CD signals of DOX are largely shielded when loaded in BG, which may be caused by the high opacity of hydrophobic nanoparticles in water suspension. In summary, the drug encapsulation mechanisms of SSG and GG are based on chiral interactions between DOX and β-glucan helical moieties.Figure 4CD spectral analysis for the DOX loaded NCs (**A**). UV-Vis spectra for the DOX loaded NCs (**B**). FT-IR spectra for the DOX loaded NCs (**C**).

UV-Vis spectra were performed to analyze the DOX loading mechanism of NCs further. As shown in [Figure 4B](#F0004){ref-type="fig"}, both GG-DOX and SSG-DOX are capable of inducing a red shift of λ~max~ of DOX from 481 to 486 nm and from 481 to 492 nm, respectively, indicating that DOX may be encapsulated based on specific non-covalent interactions such as chiral interactions, rather than physical absorption. However, no obvious red shifts occur when DOX was loaded in YG, suggesting that DOX was entrapped by non-specific absorption. That shows no absorption peak for BG-DOX NCs from 450 to 550 nm and the peak of DOX may be shielded by high opacity of BG suspension.

FT-IR was used to verify the encapsulation of DOX in NCs. [Figure 4C](#F0004){ref-type="fig"} shows the FT-IR spectra of DOX, YSG, and NCs-DOX. For YSG, the absorption at ∼3395 cm^−1^ (O-H stretching), ∼2920 cm^−1^ (C-H stretching), ∼1646 cm^−1^ (C-O stretching), ∼1153 cm^−1^ (bridge-O stretching) and ∼1077 cm^−1^ (secondary O-H stretching) can be attributed to β-glucan. For butyryl β-glucan, the new peak at ∼1738 cm^−1^ corresponding to the C=O stretch vibration demonstrated the successful esterification. For DOX, the characteristic absorption peak at ∼1572 cm^−1^ assigned to the stretching band of the aromatic rings of DOX. Compared with the free DOX and NCs, the appearance of typical bands at ∼1572 cm^−1^ in DOX-loaded nanoparticles was a proof that DOX was successfully loaded in YG, GG, SSG and BG NCs. Moreover, the higher absorbance of ∼1572 cm^−1^ indicated that GG and SSG have better DOX loading capacity.

The Drug Release Profile of the NCs-DOX {#S0003-S2005}
---------------------------------------

The drug release profile of the NCs-DOX were evaluated under normal physiological conditions (pH = 7.4) and under tumor microenvironment where the pH value is lower than the normal tissue (pH = 5.0). The drug release behavior of the above four nanoparticles was determined by a dialysis method in PBS of pH = 7.4 and pH = 5.0. The results ([Figure 5](#F0005){ref-type="fig"}) show that 30%, 26% and 24% of the loaded DOX was released from BG-DOX, SSG-DOX and GG-DOX within 12 h at pH = 5.0, respectively. However, only 18% of the loaded DOX was released from YG-DOX. The cumulative release of DOX in the buffer of pH = 5.0 revealed a sustained release over the entire period of study. For BG-DOX, the cumulative release reaches a plateau with 41% of DOX and the YG-DOX, GG-DOX, SSG-DOX were 20%, 36%, 38% of DOX, respectively. Thus, the higher release rate of SSG-DOX and GG-DOX over YG-DOX may indicate that the chiral interactions between DOX and NCs can be affected by pH change of microenvironment, resulting in a pH-sensitive DOX release.Figure 5In vitro release profiles of DOX from NCs at pH = 5.0 and pH = 7.4 within 72 h.

Cellular Uptake and Cytotoxicity {#S0003-S2006}
--------------------------------

Fluorescence microscopy was used to study the cellular uptake of free DOX and NCs-DOX. DOX kills tumor cell by intercalating DNA and RNA in the nuclei. In addition, free DOX diffuses into nuclei because of their high affinity with nucleic acids, but normal nanoparticles that are internalized through endocytosis pathway generally entrap the DOX in endosome/lysosome. [Figure 6A](#F0006a){ref-type="fig"} illustrates the observation on cellular uptakes of free DOX and NCs-DOX into MCF-7 after 4 h and 12 h. For free DOX and YG-DOX, GG-DOX, SSG-DOX, it can be observed that red fluorescence concentrated around the nucleus area after 4 h and entered into the nucleus after 12 h, indicating that YG-DOX, GG-DOX, SSG-DOX NCs can successfully deliver DOX to the nuclear region to kill cancer cells.Figure 6Continued.Figure 6Fluorescence microscopic images of MCF-7 cells treated with DOX loaded NCs and free DOX for 4 h and 12 h (**A**). Cytotoxicity of DOX loaded NCs and free DOX against MCF-7 cells for 24 h and 48 h (**B**). \*p \< 0.05, \*\*p \< 0.01.

As for BG-DOX, the cells exhibited strongest red fluorescence after treatment with the BG-DOX NCs compared with the free DOX and other NCs-DOX both after 4 h and 12 h. However, BG-DOX shows severe aggregation in the medium. Excessive hydrophobic groups in BG may cause the absorption of proteins and cause deformation of cell membrane. The red fluorescence of BG-DOX was uneven distribution and few in the area of nucleus suggesting that BG-DOX NCs are not efficient to deliver drugs to the nuclear region successfully. In summary, GG and SSG NCs effectively deliver DOX into the cell and into the nucleus. However, BG is not conducive to drug delivery may cause by its excessive presence of hydrophobic groups.

MTT cell proliferation assay was employed to measure the cellular toxicity of free DOX and NCs-DOX ([Figure 6B](#F0006b){ref-type="fig"}). For the analysis of antiproliferative activities at 24 h and 48 h, NCs-DOX and free DOX against MCF-7 cells were gradually improved with time and the increased concentration of DOX. After incubation of 24 h, the half-maximal inhibitory concentration (IC~50~) value ([Table 2](#T0002){ref-type="table"}) of DOX (3.328 μg/mL) was extremely smaller than that of YG-DOX (11.74 μg/mL), GG-DOX (6.736 μg/mL), SSG-DOX (9.213 μg/mL) and BG-DOX (20.13 ug/mL) suggesting that the free DOX exerted stronger cytotoxicity compared with NCs-DOX. This might be attributed to the fact that the free DOX with low molecular weight could be internalized rapidly via diffusion approach and displayed antiproliferative function through inhibiting nucleic acid synthesis. As for the NCs-DOX, it had to release DOX under the acid microenvironment before exhibiting cytotoxicity, which was in keeping with the analysis of cellular uptake results. Table 2IC~50~(Ug/Ml) of DOX and NCs-DOX for MCF-7 CellIC~50~(ug/mL)24h48hDOX3.3281.331YG-DOX11.745.087GG-DOX6.7362.862SSG-DOX9.2132.274BG-DOX20.135.244[^3]

Conclusion {#S0004}
==========

A series of chiral nanoparticles based on polysaccharides β-glucan were prepared by simple denaturation-renaturation approaches and their nanostructures and chiral properties were characterized by various spectroscopy and microscopy techniques. The incorporation of anti-cancer drug DOX into these nanoparticles induced drastic changes in the CD spectra of DOX, indicating a special chiral interaction between the carrier and the drug. In addition, these chiral active nanoparticles also show strong immunopotentiation ability and high drug loading efficiency. These nanoparticles can be developed as a novel type of nanomedicine for anti-cancer treatment.
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